Gilead Sciences GILD Valuation Implications of Expanded Kymera Therapeutics Collaboration and Kymeras FDA Fast Track Designation FNKO Funko blows past Q4 2025 EPS estimates but shares dip slightly in daily trading Is Banco Macro BMA stock fading in strength Q4 2025 Profit Exceeds Views